SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001725160-24-000043
Filing Date
2024-02-12
Accepted
2024-02-12 20:22:44
Documents
1
Period of Report
2024-02-12

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1707787354.html 4  
1 FORM 4 wk-form4_1707787354.xml 4 3846
  Complete submission text file 0001725160-24-000043.txt   5481
Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Issuer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ZENTALIS PHARMACEUTICALS, INC. 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address
Epperly Melissa B, (Reporting) CIK: 0001807359 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39263 | Film No.: 24622201